Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs
Abstract
Metabolic disease is a global health epidemic with detrimental effects on reproduction. The rising use of sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have introduced new treatment options, however there is little data examining their impact on reproductive safety and efficacy during pregnancy. This review summarizes how these medications may impact hormonal regulation, limit pregnancy complications, and prevent the progression of gestational diabetes into type II diabetes post-partum. Due to safety concerns, clinical data on the use of these medications during pregnancy is limited to retrospective studies of inadvertent exposure, and the limited data on possible teratogenic effects warrants further analysis, especially considering the promising results observed in pre-clinical studies.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.